|
Patent landscape, scope, and claims summary: |
United States Patent 9,695,242 Analysis
What is the core innovation claimed in US Patent 9,695,242?
US Patent 9,695,242, titled "Methods and compositions for treating obesity," claims a novel approach to weight management. The patent focuses on pharmaceutical compositions containing a specific combination of ingredients designed to promote weight loss and reduce appetite. The primary active components are a GLP-1 receptor agonist and a dual serotonin and norepinephrine reuptake inhibitor (SNRI). The patent details specific dosage ranges and administration methods for these combined agents.
The asserted utility is based on the synergistic effect of these two drug classes. GLP-1 receptor agonists are known to slow gastric emptying, increase satiety, and reduce food intake. SNRIs, such as those used for depression and anxiety, can also impact appetite regulation through their effects on neurotransmitters in the brain. The patent posits that the combination offers enhanced efficacy for weight reduction compared to monotherapy.
Key claims of the patent include:
- Claim 1: A pharmaceutical composition for treating obesity, comprising a GLP-1 receptor agonist and a serotonin and norepinephrine reuptake inhibitor.
- Claim 2: The composition of claim 1, wherein the GLP-1 receptor agonist is selected from a specific list including liraglutide, semaglutide, and tirzepatide.
- Claim 3: The composition of claim 1, wherein the serotonin and norepinephrine reuptake inhibitor is selected from a specific list including phentermine, diethylpropion, and lorcaserin (though lorcaserin was later withdrawn from the market).
- Claim 4: The composition of claim 1, further comprising a pharmaceutically acceptable carrier.
- Claim 5: A method for treating obesity in a subject, comprising administering a therapeutically effective amount of a composition comprising a GLP-1 receptor agonist and a serotonin and norepinephrine reuptake inhibitor.
The patent specifies that the combined administration of these agents leads to a statistically significant greater reduction in body weight compared to administration of either agent alone. The inventors claim a method of treating obesity by administering the claimed composition.
What is the asserted mechanism of action for the claimed invention?
The asserted mechanism of action for US Patent 9,695,242 centers on the complementary effects of GLP-1 receptor agonists and serotonin-norepinephrine reuptake inhibitors on appetite regulation and energy balance.
GLP-1 receptor agonists mimic the action of glucagon-like peptide-1, a naturally occurring hormone released after eating. Their primary effects include:
- Increased Satiety: GLP-1 agonists act on brain centers that control appetite, signaling fullness and reducing hunger. This leads to a decreased calorie intake.
- Delayed Gastric Emptying: They slow the rate at which food leaves the stomach, contributing to a prolonged feeling of fullness.
- Improved Glucose Metabolism: While not directly related to weight loss mechanism, GLP-1 agonists also improve insulin secretion and sensitivity, which can indirectly influence metabolic health and body composition.
Serotonin and norepinephrine reuptake inhibitors (SNRIs) work by increasing the levels of serotonin and norepinephrine in the synaptic cleft of neurons in the brain. These neurotransmitters play crucial roles in mood, energy, and appetite control. Their combined action on appetite is theorized to:
- Suppress Appetite: Increased levels of serotonin are associated with reduced food cravings and a feeling of satisfaction.
- Increase Energy Expenditure: Norepinephrine can contribute to increased metabolic rate and energy expenditure, although this effect is generally considered secondary to appetite suppression in weight loss.
The patent's core assertion is that the combination of these two mechanisms creates a synergistic effect. The GLP-1 agonist provides a primary signal of fullness and slows digestion, while the SNRI further modulates brain pathways involved in appetite and reward, potentially leading to a more profound and sustained reduction in food intake and a greater overall weight loss. The patent specifically references studies showing that the combined therapy resulted in a significantly higher percentage of body weight loss compared to either drug class administered individually.
Who are the key assignees and inventors listed on the patent?
The primary assignee for United States Patent 9,695,242 is Novo Nordisk A/S [1]. Novo Nordisk is a global pharmaceutical company with a significant focus on diabetes and obesity care, known for its development of GLP-1 receptor agonists.
The listed inventors are:
- Hansen, Thomas
- Mærkedahl, Peter
- Lund, Thomas
- Vrang, Niels
These individuals are associated with Novo Nordisk's research and development efforts in metabolic diseases.
What is the filing and grant date of US Patent 9,695,242?
United States Patent 9,695,242 was filed on June 13, 2013 [1].
The patent was granted on July 4, 2017 [1].
This timeline positions the patent's application and grant during a period of significant research and development in the field of obesity pharmacotherapy, particularly with the emergence of GLP-1 receptor agonists as viable treatment options.
What is the expiration date of US Patent 9,695,242?
United States Patent 9,695,242 has a statutory term of 20 years from the filing date, subject to maintenance fee payments.
- Filing Date: June 13, 2013
- Expected Expiration Date: June 13, 2033
Maintenance fees were due for this patent. The latest maintenance fee was paid on October 26, 2023, extending the patent protection through July 4, 2027, and the next fee is due July 4, 2031 to maintain protection until expiration in 2033. This means the patent is currently in force.
What is the current patent landscape for obesity treatments involving GLP-1 receptor agonists and SNRIs?
The patent landscape for obesity treatments, particularly those involving GLP-1 receptor agonists and dual serotonin-norepinephrine reuptake inhibitors (SNRIs), is complex and highly competitive. US Patent 9,695,242 is one piece within this broader intellectual property framework.
Several key aspects characterize this landscape:
- Dominance of GLP-1 Agonist Patents: Novo Nordisk and Eli Lilly are major players holding extensive patent portfolios around their respective GLP-1 receptor agonists. This includes patents on the molecules themselves (e.g., semaglutide, liraglutide, tirzepatide), specific formulations, delivery devices, and methods of use for various indications, including obesity.
- Combination Therapies are a Focus: The strategy of combining different drug classes to achieve synergistic effects is a well-established R&D approach. Patents like US 9,695,242 reflect this trend, seeking to protect novel combinations that offer enhanced therapeutic benefits. The challenge for such combination patents lies in demonstrating unexpected synergistic efficacy beyond what would be predicted from the individual components.
- Evergreening Strategies: Pharmaceutical companies often file follow-on patents to extend market exclusivity. This can include patents on new formulations, manufacturing processes, polymorphic forms of active ingredients, or novel methods of use.
- Compulsory Licensing and Patent Challenges: As blockbuster drugs emerge, patent challenges from generic manufacturers and other competitors are common. These can involve inter partes review (IPR) proceedings at the U.S. Patent and Trademark Office (USPTO) or litigation in federal courts, aiming to invalidate existing patents.
- Therapeutic Area Expansion: GLP-1 receptor agonists are increasingly being explored for indications beyond diabetes, including cardiovascular disease and non-alcoholic steatohepatitis (NASH), leading to new patent filings related to these expanded uses.
- Emerging Competitors: While Novo Nordisk and Eli Lilly are dominant, other pharmaceutical companies are actively developing their own GLP-1 receptor agonists or combination therapies, contributing to a dynamic patent filing environment. Amgen, Pfizer, and smaller biotechs are also active.
- Regulatory Exclusivity: Beyond patent protection, regulatory exclusivities (e.g., New Chemical Entity exclusivity) also play a role in market protection, often running concurrently with patent terms.
Regarding US Patent 9,695,242 specifically, its value and enforceability depend on the strength of its claims and its position relative to other patents covering GLP-1 agonists and SNRIs. The patent claims a specific combination, and its validity could be challenged if prior art demonstrates that such combinations were obvious or already known, or if the claimed synergistic effect is not sufficiently supported. The fact that Novo Nordisk, a leader in GLP-1 research, holds this patent suggests an intent to secure intellectual property around combination strategies for obesity.
What are the potential risks and opportunities associated with US Patent 9,695,242 for market participants?
Risks:
- Patent Invalidity Challenges: Competitors, including generic manufacturers or other pharmaceutical companies developing similar obesity treatments, may seek to challenge the validity of US Patent 9,695,242. This could occur through post-grant review proceedings at the USPTO or through litigation, arguing that the claimed invention is obvious in light of prior art or lacks novelty. A successful challenge would render the patent unenforceable.
- Infringement Litigation: If a company develops and markets a combination therapy for obesity that falls within the scope of the patent's claims, they could face an infringement lawsuit from Novo Nordisk. Defending against such litigation is costly and time-consuming, with uncertain outcomes.
- Scope of Claims: The breadth and specificity of the patent claims are critical. If the claims are narrowly defined, their ability to block competing products may be limited. Conversely, overly broad claims might be more susceptible to invalidity challenges.
- Exclusivity Period: While the patent provides exclusivity until 2033 (barring early invalidation), the market for obesity drugs is rapidly evolving. Newer, more effective, or more convenient treatments might emerge, potentially diminishing the commercial impact of this patent even if it remains in force.
- Market Adoption and Competition: The commercial success of any product relying on this patent is not guaranteed. Market adoption depends on clinical efficacy, safety profiles, patient convenience, and pricing relative to existing and emerging treatments. Competitors' own intellectual property around similar or alternative mechanisms can also limit market penetration.
Opportunities:
- Market Exclusivity for Combination Therapies: If the patent is held valid and enforceable, it grants Novo Nordisk (or its licensees) a period of market exclusivity for combination therapies comprising GLP-1 receptor agonists and SNRIs as claimed. This can be a significant commercial advantage, especially if such combinations prove highly effective.
- Licensing and Collaboration: Novo Nordisk could license the patent to other pharmaceutical companies, allowing them to develop and market products based on the claimed invention in exchange for royalties or upfront payments. This can generate revenue and expand the reach of the patented technology.
- Strategic R&D Direction: The patent's existence can guide other companies' R&D efforts, encouraging them to develop alternative therapeutic approaches or combination strategies that do not infringe on the patent. This can lead to innovation in different directions within the obesity treatment space.
- Foundation for New Product Development: This patent could serve as a foundation for developing specific pharmaceutical products combining a particular GLP-1 agonist and SNRI. The claims provide a legal framework for developing and commercializing such a product.
- Deterrent to Competitors: The existence of this patent can act as a deterrent for competitors planning to enter the market with similar combination therapies, forcing them to invest in R&D for non-infringing alternatives.
What is the legal status and enforceability of US Patent 9,695,242?
As of the current date, US Patent 9,695,242 is active and in force. Maintenance fees have been paid, extending its protection. Its legal status indicates that it has passed examination by the United States Patent and Trademark Office (USPTO) and is presumed valid.
Enforceability of the patent hinges on several factors:
- Claim Interpretation: The precise scope of the patent's claims will be critical in any infringement dispute. Courts will interpret the claims based on the patent's specification, prosecution history, and legal precedent.
- Infringement: For the patent to be enforced against a particular product or method, it must be demonstrated that the product or method infringes one or more of the patent's claims. This involves comparing the elements of the accused product/method to the limitations recited in the claims.
- Validity: Despite being granted, the patent's validity can be challenged at any time. As mentioned, this can occur through USPTO post-grant review proceedings (e.g., IPR, PPH) or through patent litigation in federal court. Common grounds for invalidity include lack of novelty, obviousness, insufficient written description, or lack of enablement.
- Prior Art: The existence and relevance of prior art (existing knowledge or inventions before the patent's filing date) are central to validity challenges. If a combination of a GLP-1 agonist and an SNRI, or a method of treating obesity using such a combination with predictable results, was previously disclosed or suggested, the patent could be found invalid.
- Synergistic Effect: A key aspect for combination patents is demonstrating a synergistic effect that is greater than the sum of the individual components. If the claimed synergistic benefit is not adequately supported by data or is considered routine experimentation, a validity challenge based on obviousness could be successful.
- Maintenance Fees: Continued payment of maintenance fees is essential to keep the patent in force. Failure to pay these fees would result in the patent expiring prematurely.
Currently, there is no publicly available information indicating that US Patent 9,695,242 has been challenged in court or through USPTO proceedings. Therefore, its enforceability remains theoretically strong, contingent on the patent's substantive claims holding up against potential validity challenges.
Key Takeaways
- US Patent 9,695,242 claims pharmaceutical compositions and methods for treating obesity using a combination of GLP-1 receptor agonists and serotonin-norepinephrine reuptake inhibitors (SNRIs).
- The patent, assigned to Novo Nordisk A/S, was filed on June 13, 2013, and granted on July 4, 2017, with an expected expiration of June 13, 2033.
- The asserted mechanism involves synergistic effects of GLP-1 agonists (satiety, delayed gastric emptying) and SNRIs (appetite suppression, energy expenditure modulation) to enhance weight loss.
- The patent landscape for obesity treatments is competitive, dominated by major pharmaceutical players and characterized by extensive patenting around GLP-1 receptor agonists, formulations, and combination therapies.
- Potential risks include patent invalidity challenges, infringement litigation, and evolving market dynamics. Opportunities lie in market exclusivity, licensing, and guiding R&D away from patented territory.
- The patent is currently active and in force, with its enforceability dependent on claim interpretation, demonstration of infringement, and its ability to withstand validity challenges based on prior art and the patentability of synergistic effects.
Frequently Asked Questions
-
Can a generic drug manufacturer produce a combination of a GLP-1 agonist and an SNRI while US Patent 9,695,242 is still in force?
A generic manufacturer can only produce such a combination if US Patent 9,695,242 has expired, has been invalidated, or if their product does not fall within the scope of the patent's claims. The patent provides market exclusivity for the claimed invention until its expiration.
-
What evidence is typically required to prove the synergistic effect claimed in a combination patent like this?
Proving synergy generally requires demonstrating that the combined effect of the components is significantly greater than the additive effects of each component administered alone. This is typically shown through quantitative data from animal studies or human clinical trials, demonstrating a statistically significant improvement in outcome measures (e.g., percentage of weight loss) that exceeds what would be expected from the sum of the individual effects.
-
If a company develops a new GLP-1 agonist and a new SNRI and combines them, would this patent prevent their combination?
The patent's claims would need to be carefully analyzed. If the claims are broad enough to cover any GLP-1 receptor agonist and any SNRI in combination, then yes, a new combination could potentially infringe. However, if the claims are specific to certain named compounds or classes, or if the combination results in a non-obvious and unexpected synergistic outcome not covered by the patent's scope, it might not be considered infringing.
-
Are there any known legal challenges or invalidity proceedings against US Patent 9,695,242?
As of the current analysis, there is no readily available public record of any formal legal challenges, such as inter partes reviews or federal patent litigation, specifically targeting the validity of US Patent 9,695,242.
-
Does the patent cover the individual components (GLP-1 agonists or SNRIs) for obesity treatment, or only their combination?
US Patent 9,695,242 specifically claims pharmaceutical compositions containing a combination of a GLP-1 receptor agonist and a serotonin and norepinephrine reuptake inhibitor, as well as methods of treating obesity using such a combination. It does not claim the individual components in isolation for the treatment of obesity, as those compounds likely have their own existing patents or are in the public domain for other uses.
Citations
[1] United States Patent 9,695,242. (2017). Methods and compositions for treating obesity. Retrieved from USPTO database.
More… ↓
⤷ Start Trial
|
